Codexis reported second quarter 2026 financial results with total revenues of $14.9 million, a slight decrease from $15.3 million in the prior year period. The company completed an equity financing in July raising approximately $25 million in net proceeds, bringing proforma cash to roughly $80 million. Net loss for the quarter was $12.0 million, or $0.13 per share, compared to a $13.3 million loss in Q2 2025. The company reiterated its full-year 2026 revenue guidance of $72 million to $76 million and expects existing cash resources to fund operations through the end of 2028. Codexis operates in the biotechnology industry, providing enzymatic solutions for the manufacturing of complex therapeutics.

Codexis, Inc. completed a public offering of 16,666,677 shares of common stock at $1.50 per share, generating approximately $23.1 million in net proceeds. The offering was underwritten by Piper Sandler & Co. and Cantor Fitzgerald & Co. as representatives. Codexis, Inc. is a biotechnology company that develops enzyme-based solutions for industrial and pharmaceutical applications.

Codexis, Inc. expects to report at least $14.8 million in total revenue for the three months ended June 30, 2026, and approximately $54.9 million in cash, cash equivalents, and short-term investments for the same period. These figures are preliminary estimates based on management's reviews. Codexis, Inc. is a biotechnology company that develops enzyme-based solutions for industrial and pharmaceutical applications.